Power Law company profile

Celator Pharmaceuticals

Biotech & Life Sciences · Dublin, Ireland · Founded 1999 · IPO 2013 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$1.50B

Market cap · 2026

Investors

8 investors on Celator Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Seed 1 investor entered at this stage

Business Development Bank of Canada

Series B+ 7 investors entered at this stage

Valence Life Sciences

Domain Associates

TL Ventures

Thomas McNerney & Partners

Ventures West

BC Cancer Agency

ROTH Capital Partners

Patent intelligence

$32M patent portfolio · 14 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with topic prominence vs same-sector peers.

Estimated portfolio value

$32M

2.2% of market cap · 5.1× smaller than top peer Amicus Therapeutics ($164M)

14 active patent families

Where Celator Pharmaceuticals innovates PharmacologyDrugTherapeutic effectDelivery vehicleCamptothecin

Tech-focus vs peers

Where Celator Pharmaceuticals concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Celator Pharmaceuticals and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Celator Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo